Increased Uptake of 68Ga-DOTA-IBA in Multiple Subcutaneous Metastases of Prostate Cancer

被引：4
作者：
Liu, Huipan [1 ,2 ,3 ]
Liu, Yuhong [4 ]
Wang, Wei [1 ,2 ,3 ]
Shang, Xiaoyan [1 ,2 ,3 ]
Chen, Yue [1 ,2 ,3 ]
机构：
[1] Southwest Med Univ, Affiliated Hosp, Dept Nucl Med, 25 TaiPing St, Luzhou 646000, Sichuan, Peoples R China
[2] Southwest Med Univ, Nucl Med & Mol Imaging Key Lab Sichuan Prov, Luzhou, Sichuan, Peoples R China
[3] Southwest Med Univ, Inst Nucl Med, Luzhou, Sichuan, Peoples R China
[4] Southwest Med Univ, Affiliated Hosp, Dept Oncol, Luzhou, Sichuan, Peoples R China
来源：
CLINICAL NUCLEAR MEDICINE | 2024年 / 49卷 / 11期
关键词：
Ga-68-DOTA-IBA; PET/CT; subcutaneous metastasis; prostate cancer; extraosseous uptake; BONE METASTASES; LU-177-DOTA-IBA; THERAPY;
D O I：
10.1097/RLU.0000000000005462
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Subcutaneous metastases are rare in prostate cancer. Herein, we present a case of a 66-year-old man with prostate cancer, who underwent 68Ga-labeled DOTA-ibandronic acid (Ga-68-DOTA-IBA) PET/CT to explore the possibility of 177Lu-DOTA-IBA treatment. Ga-68-DOTA-IBA PET/CT demonstrated intensely increased uptake in the multiple osteoblastic bone metastases. Unexpectedly, 68Ga-DOTA-IBA uptake in multiple subcutaneous metastases was also noted.
引用
收藏
页码：1062 / 1064
页数：3
相关论文
共 10 条
[1]  
Aranzubia Oscar Miranda, 2009, Arch Esp Urol, V62, P583
[2]   Treatment of Bone Metastases of Breast Cancer With 177Lu-DOTA-IBA [J].
Deng, Jia ;
Yang, Jian ;
Cheng, Zixuan ;
Chen, Yue .
CLINICAL NUCLEAR MEDICINE, 2024, 49 (07) :659-661
[3]   Comparison of the relative diagnostic performance of 68Ga-DOTA-IBA and 18F-NaF for the detection of bone metastasis [J].
Deng, Jia ;
Yang, Jian ;
Wang, Yingwei ;
Liu, Guangfu ;
Chen, Yue .
FRONTIERS IN ONCOLOGY, 2024, 14
[4]   Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases [J].
Li, Hongmei ;
Pei, Wenjie ;
Yang, Xiqun ;
Qu, Gengcuo ;
Hua, Qingchu ;
Liu, Lin ;
Wang, Yudi ;
Xu, Tingting ;
Chen, Yue .
EJNMMI RESEARCH, 2024, 14 (01)
[5]   177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases [J].
Li, Hongmei ;
Xu, Tingting ;
Hua, Qingchu ;
Wang, Li ;
Chen, Yue .
CLINICAL NUCLEAR MEDICINE, 2023, 48 (08) :740-742
[6]   68Ga-DOTA-Ibandronic Acid PET/CT in a Patient With Chemotherapy-Induced Salivary Gland Hypofunction [J].
Liu, Ya ;
Ding, Haoyuan ;
Zhang, Ting ;
Chen, Yue ;
Huang, Zhanwen .
CLINICAL NUCLEAR MEDICINE, 2024, 49 (05) :470-471
[7]   Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases A Phase 0/I Study [J].
Qiu, Lin ;
Wang, Yingwei ;
Liu, Hanxiang ;
Wang, Qixin ;
Chen, Lin ;
Liu, Lin ;
Wang, Li ;
Feng, Yue ;
Chen, Yue .
CLINICAL NUCLEAR MEDICINE, 2023, 48 (06) :489-496
[8]   Lutetium177-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases [J].
Wang, Qixin ;
Yang, Jian ;
Wang, Yingwei ;
Liu, Hanxiang ;
Feng, Yue ;
Qiu, Lin ;
Chen, Yue .
MOLECULAR PHARMACEUTICS, 2023, 20 (03) :1788-1795
[9]   68Ga-DOTA-IBA Uptake in Breast cancer [J].
Xiang, Feifan ;
Liu, Huipan ;
Tan, Xiaoqi ;
Chen, Yue .
CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) :574-575
[10]   Biodistribution and Internal Dosimetry of 68Ga-DOTA-IBA PET Imaging for Patients With Bone Metastases [J].
Yang, Jian ;
Deng, Jia ;
Fan, Dongmei ;
Chen, Gefei ;
Lu, Zhonglin ;
Liu, Hanxiang ;
Mok, Greta S. P. ;
Chen, Yue .
CLINICAL NUCLEAR MEDICINE, 2023, 48 (10) :847-852
1